Ani i\u015fitme kayb\u0131 hasta i\u00e7in \u00fcrk\u00fct\u00fcc\u00fc ve huzur ka\u00e7\u0131r\u0131c\u0131 bir rahats\u0131zl\u0131kt\u0131r. \u0130\u015fitme kay\u0131plar\u0131n\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011fu tek tarafl\u0131 olmas\u0131na ra\u011fmen \u015fanss\u0131z az\u0131nl\u0131k i\u00e7in iki tarafl\u0131 i\u015fitme kayb\u0131 olu\u015fabilir.<\/p>\n
Yandaki odyogramda hastan\u0131n sa\u011f kula\u011f\u0131ndaki ani i\u015fitme kayb\u0131 de\u011ferleri k\u0131rm\u0131z\u0131 renkle g\u00f6sterilmi\u015ftir.<\/p>\n
TANIM: <\/strong>3 g\u00fcn i\u00e7inde birbirini takip eden 3 frekansta 30 db ve \u00fczerindeki kay\u0131pt\u0131r.<\/p>\n EP\u0130DEM\u0130YOLOJ\u0130: <\/strong>Ani i\u015fitme kayb\u0131n\u0131n y\u0131ll\u0131k insidans\u0131 100.000 ki\u015fide 5 ile 20 ki\u015fi aras\u0131nda de\u011fi\u015fir. Kad\u0131n erkek oran\u0131 e\u015fit da\u011f\u0131l\u0131m g\u00f6sterir. Cinsiyet bir risk fakt\u00f6r\u00fc de\u011fildir. \u0130ki tarafl\u0131 ani i\u015fitme kayb\u0131 vakalar\u0131n %1 ile %2\u2019sinde g\u00f6r\u00fcl\u00fcr.<\/p>\n Ani i\u015fitme kayb\u0131 t\u00fcm ya\u015f gruplar\u0131nda g\u00f6r\u00fcl\u00fcr. En \u00e7ok 40 \u2013 54 y\u0131l aras\u0131nda de\u011fi\u015fir.<\/p>\n AYIRICI TANI: <\/strong>Ani i\u015fitme kayb\u0131 nedeni belirli ve nedeni belirli olmayan ( idiopatik ) ani sens\u00f6rin\u00f6ral i\u015fitme kayb\u0131 olarak 2 alt gruba ayr\u0131l\u0131r. Ani i\u015fitme kay\u0131pl\u0131 vakalar\u0131n \u00e7o\u011funlu\u011fu idiopatiktir.<\/p>\n Ani i\u015fitme kayb\u0131nda menenjit , labirentit ( i\u00e7 kulak hastal\u0131\u011f\u0131 ) , sifiliz , kabakulak gibi enfeksiyonlar , multipl skleroz gibi bir enflamasyon , kafa travmas\u0131 veya akustik travma , beyin veya temporal kemik t\u00fcm\u00f6rleri , baz\u0131 ila\u00e7lar veya damar hastal\u0131klar\u0131 sebep olabilirler.<\/p>\n \u0130diopatik ani i\u015fitme kayb\u0131n\u0131n nedenini a\u00e7\u0131klayan 3 ana varsay\u0131m mevcuttur.<\/p>\n Viral enfeksiyonlar<\/p>\n Vask\u00fcler ( damarsal ak\u0131m ) yetmezlik<\/p>\n \u0130ntra koklear membran r\u00fcpt\u00fcr\u00fc ( y\u0131rt\u0131lmas\u0131 )<\/p>\n \u0130mm\u00fcn i\u00e7 kulak hastal\u0131\u011f\u0131 da ani i\u015fitme kayb\u0131 sebebi olabilir.<\/p>\n DE\u011eERLEND\u0130RME: <\/strong>Hastalar\u0131 de\u011ferlendirmi h\u0131zl\u0131 bir \u015fekilde yap\u0131lmal\u0131d\u0131r. Hekime erken ba\u015fvurulmas\u0131 ve tedavinin erken ba\u015flamas\u0131 i\u015fitmenin geri gelme prognozunu artt\u0131r\u0131r. Hastal\u0131\u011f\u0131n ba\u015flang\u0131c\u0131, ilerleyi\u015fi , e\u015flik eden semptomlar\u0131 ve yak\u0131n zamandaki aktiviteler yard\u0131mc\u0131 ipu\u00e7lar\u0131 verebilir. Son kullan\u0131lan t\u00fcm ila\u00e7lar sorgulanmal\u0131d\u0131r. Tam bir ba\u015f boyun muayenesi uygun olur. Komple bir odyolojik inceleme \u015fartt\u0131r. De\u011ferlendirme ve tedavi s\u00fcrecinin bir noktas\u0131nda i\u00e7 kulak kanal\u0131 ve serebellopontin a\u00e7\u0131n\u0131n g\u00f6r\u00fcnt\u00fclenmesi tavsiye edilir. Gadoliniumlu manyetik rezonans g\u00f6r\u00fcnt\u00fcleme alt\u0131n standartt\u0131r.<\/p>\n TEDAV\u0130:<\/strong><\/p>\n Say\u0131s\u0131z tedavi protokolleri uygulanm\u0131\u015ft\u0131r. Bu \u00e7e\u015fitlilik hem farkl\u0131 etyolojilerden hem de tan\u0131daki belirsizliklerden kaynaklan\u0131r.<\/p>\n Etki mekanizmalar\u0131na g\u00f6re tedaviler :<\/p>\n Vazodilat\u00f6rler : Bu ila\u00e7lar kokleaya kan ak\u0131m\u0131n\u0131 artt\u0131rarak hipoksiyi geriye d\u00f6nd\u00fcr\u00fcrler. Histamin , nikotinik asit , vb. ila\u00e7lar kullan\u0131lm\u0131\u015flard\u0131r.<\/p>\n Reolojik Ajanlar: D\u00fc\u015f\u00fck molek\u00fcler a\u011f\u0131rl\u0131kl\u0131 dekstranlar , pentoksifilin ve heparin ve warfarin gibi antikoag\u00fclanlar\u0131n kullan\u0131lmas\u0131n\u0131n amac\u0131 kan\u0131n ak\u0131\u015fkanl\u0131\u011f\u0131n\u0131 de\u011fi\u015ftirerek kan ak\u0131m\u0131n\u0131 ve oksijen da\u011f\u0131t\u0131m\u0131n\u0131 artt\u0131rmakt\u0131r.<\/p>\n Antienflamatuar \u0130la\u00e7lar: Kortikosteroidler tedavide kullan\u0131lan primer antienflamatuar ila\u00e7lard\u0131r. Prednizolon , betametason kullan\u0131lan ila\u00e7lardand\u0131r.<\/p>\n Antiviral \u0130la\u00e7lar: Asiklovir ve amantadin , famsiklovir ve valasiklovir kullan\u0131lan ajanlard\u0131r.<\/p>\n Di\u00fcretikler: Ani i\u015fitme kayb\u0131n\u0131n koklear endolenfatik hidropsa sekonder olarak geli\u015fti\u011fi varsay\u0131m\u0131 ile di\u00fcretikler tedavide kullan\u0131lm\u0131\u015ft\u0131r.<\/p>\n BULGULAR: <\/strong>Ani i\u015fitme kayb\u0131nda iyile\u015fme oranlar\u0131 genellikle iyidir ( %47 – %63 aras\u0131 ). Literat\u00fcrde tedavisiz takip edilen 52 hastada %58 spontan iyile\u015fme g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n TEDAV\u0130 PROTOKOLLER\u0130: <\/strong><\/p>\n Vazodilat\u00f6r terapisi tek ba\u015f\u0131na anlaml\u0131 de\u011fildir.<\/p>\n D\u00fc\u015f\u00fck molek\u00fcler a\u011f\u0131rl\u0131kl\u0131 dekstranlar ile yap\u0131lan \u00e7al\u0131\u015fmalarda \u00fcst\u00fcn bir iyile\u015fme oran\u0131 g\u00f6r\u00fclmemi\u015ftir.<\/p>\n Kortikosteroid tedavisinde farkl\u0131 tedavi sonu\u00e7lar\u0131 g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. \u0130yile\u015fme oranlar %41 – %60 aras\u0131nda de\u011fi\u015fmektedir.<\/p>\n Transtimpanik steroid uygulamalar\u0131n\u0131n teorik olarak i\u00e7 kula\u011fa y\u00fcksek yo\u011funlukta ila\u00e7 uygularken sistemik yo\u011funlu\u011fun d\u00fc\u015f\u00fck olmas\u0131 gibi bir faydas\u0131 vard\u0131r. \u00c7al\u0131\u015fmalar steroid tedavisinin etkinli\u011fini vurgulam\u0131\u015ft\u0131r.<\/p>\n CERRAH\u0130: <\/strong>Pozitif fist\u00fcl testi olan hastalarda veya ge\u00e7irilmi\u015f travma hikayesi olan hastalarda oval veya yuvarlak penceredeki perilenf fist\u00fcl onar\u0131m\u0131 yap\u0131labilir.<\/p>\n Tedavilerde prednizolon ve asiklovir tek ba\u015f\u0131na prednizolon tedavisi ile k\u0131yaslanm\u0131\u015ft\u0131r. Tek ba\u015f\u0131na prednizolon kullan\u0131lmas\u0131n\u0131n, asiklovir ile prednizolonun beraber kullan\u0131lmas\u0131ndan farkl\u0131 bir tedavi sonucu sunmad\u0131\u011f\u0131 g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n Tedavinin sonucunu \u00f6nceden tahmin edebilmek i\u00e7in baz\u0131 prognostik sebepler \u00f6ne s\u00fcr\u00fclm\u00fc\u015ft\u00fcr. Ba\u015f d\u00f6nmesi ve dengesizlik semptomlar\u0131n\u0131n daha d\u00fc\u015f\u00fck bir iyile\u015fme oran\u0131na delalet etti\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n SONU\u00c7LAR: <\/strong>Ani i\u015fitme kayb\u0131 tedavisinde doktora erken ba\u015fvuru, hastan\u0131n derhal istirahate al\u0131nmas\u0131 , serumla beslenmesi ve gerekli medikal tedavinin uygulanmas\u0131 esast\u0131r. Steroid tedavisi kullan\u0131lan ila\u00e7lar i\u00e7inde en etkili ajan kabul edilmektedir. Son g\u00fcnlerde hiperbarik oksijen tedavileri medikal tedaviye ilaveten uygulamaya girmi\u015ftir.<\/p>\n Ani i\u015fitme kayb\u0131 i\u00e7in bir\u00e7ok tedavi protokol\u00fc mevcuttur ve uygulanan t\u00fcm tedavinin alt\u0131nda yatan mant\u0131\u011f\u0131n bilinmesi gereklidir.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Ans\u0131z\u0131n i\u015fitme kayb\u0131! Konu hakk\u0131nda detayl\u0131 ve g\u00fcncel bilgiler i\u00e7in bu makaleyi okuyun<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[25,36,353,42],"class_list":["post-2908","post","type-post","status-publish","format-standard","hentry","category-kulak-burun-bogaz","tag-hasta","tag-isitme-kaybi","tag-iyilesme","tag-tedavi"],"_links":{"self":[{"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/posts\/2908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/comments?post=2908"}],"version-history":[{"count":1,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/posts\/2908\/revisions"}],"predecessor-version":[{"id":2909,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/posts\/2908\/revisions\/2909"}],"wp:attachment":[{"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/media?parent=2908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/categories?post=2908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/odyova.com\/haberler\/wp-json\/wp\/v2\/tags?post=2908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}